Research needs in the area of device-related treatments for hypertension

Kidney International

Volumn 84, Issue 2, 2013, Pages 250-255

  Jordan, Jens ^a   Mann, Johannes F ^b   Luft, Friedrich C ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Klinikum Schwabing   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Autonomic nervous system; Medical devices; Refractory hypertension; Renal denervation; Resistant hypertension; Sympathetic nervous system

Indexed keywords

BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; DISEASE MODEL; ELECTRICAL CAROTID SINUS STIMULATION; ELECTROSTIMULATION THERAPY; EVIDENCE BASED MEDICINE; FOLLOW UP; HISTOLOGY; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MEDICAL DEVICE; MEDICAL RESEARCH; NONHUMAN; PERCUTANEOUS CATHETER BASED RENAL SYMPATHETIC DENERVATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REINNERVATION; REVIEW; SAFETY; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BIOMEDICAL RESEARCH; BLOOD PRESSURE; CAROTID SINUS; CATHETER ABLATION; DIFFUSION OF INNOVATION; ELECTRIC STIMULATION THERAPY; EQUIPMENT DESIGN; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84881161924     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.56     Document Type: Short Survey

References (42)

1. Krum H, Sobotka P, Mahfoud F et al. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011; 123: 209-215.
2. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension 2011; 57: 880-886.
3. Grimson KS. Total thoracic and partial to-total lumbar sympathetctomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg 1941; 114: 753-775.
4. Peters TK, Koralewski HE, Zerbst E. The principle of electrical carotid sinus nerve stimulation: a nerve pacemaker system for angina pectoris and hypertension therapy. Ann Biomed Eng 1980; 8: 445-458. (Pubitemid 11064554)
5. Rothfeld EL, Parsonnet V, Raman KV et al. The effect of carotid sinus nerve stimulation on cardiovascular dynamics in man. Angiology 1969; 20: 213-218.
6. Parsonnet V, Rothfeld EL, Raman KV et al. Electrical stimulation of the carotid sinus nerve. Surg Clin North Am 1969; 49: 589-596.
7. Dibona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R245-R253.
8. Bernard C. Leçons sur les Propriétés et les Altérations Pathologiques des Liquides de L'Organisme Bailliére et Fils: Paris, 1859; vol. 2: 170-171.
9. Kopp UC, Smith LA, Dibona GF. Renorenal reflexes: neural components of ipsilateral and contralateral renal responses. Am J Physiol 1985; 249: F507-F517. (Pubitemid 16185882)
10. Cowley AJ, Liard JF, Guyton AC. Role of baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. Circ Res 1973; 32: 564-576.
11. KRIEGER EM. Neurogenic hypertension in the rat. Circ Res 1964; 15: 511-521.
12. Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1044-R1053. (Pubitemid 34664556)
13. Tordoir JH, Scheffers I, Schmidli J et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg 2007; 33: 414-421. (Pubitemid 46336600)
14. Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56: 1254-1258.
15. Mohaupt MG, Schmidli J, Luft FC. Management of uncontrollable hypertension with a carotid sinus stimulation device. Hypertension 2007; 50: 825-828. (Pubitemid 350287517)
16. Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841.
17. Persu A, Renkin J, Thijs L et al. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012; 60: 596-60630.
18. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-ofprinciple cohort study. Lancet 2009; 373: 1275-1281.
19. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
20. Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-1946.
21. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565.
22. Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909.
23. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-1034.
24. Mann J, Hilgers K, Veelken R et al. Correspondence (letter to the editor): an experimental procedure paid for by the general public. Dtsch Arztebl Int 2012; 109: 311-312.
25. Mahfoud F, Vonend O, Bruck H et al. [Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment]. Dtsch Med Wochenschr 2011; 136: 2418.
26. Lohmeier TE, Irwin ED, Rossing MA et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004; 43: 306-311. (Pubitemid 38174130)
27. Lohmeier TE, Dwyer TM, Irwin ED et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007; 49: 1307-1314. (Pubitemid 46809373)
28. Lohmeier TE, Dwyer TM, Hildebrandt DA et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 2005; 46: 1194-1200. (Pubitemid 41533025)
29. Schmidli J, Savolainen H, Eckstein F et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular 2007; 15: 63-69. (Pubitemid 47026645)
30. Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55: 619-626.
31. Wustmann K, Kucera JP, Scheffers I et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009; 54: 530-536.
32. Bisognano JD, Bakris G, Nadim MK et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-773.
33. Bisognano JD, Kaufman CL, Bach DS et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011; 57: 1787-1788.
34. Bakris GL, Nadim MK, Haller H et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of longterm follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6: 152-158.
35. Alnima T, Scheffers I, De Leeuw PW et al. Sustained acute voltagedependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens 2012; 30: 1665-1670.
36. Bard J, Vize PD, Woolf AS. The Kidney: from Normal Devel opment to Congenital Disease. Academic Press: Boston, 2003 p. 154.
37. Symplicity HTN-1 investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
38. Vonend O, Antoch G, Rump LC et al. Secondary rise in blood pressure after renal denervation. Lancet 2012; 380: 778.
39. Rippy MK, Zarins D, Barman NC et al. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol 2011; 100: 1095-1101.
40. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
41. Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-tocontrol hypertensive patients: prospective case series. Hypertension 2012; 60: 1485-1490.
42. Hering D, Lambert EA, Marusic P et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013; 61: 457-464.